Has Nicole Langelier, MD received payments from drug or device companies?

Yes. Drug and device makers reported $663 in general payments to Nicole Langelier, MD across 15 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nicole Langelier, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nicole Langelier, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nicole Langelier, MD

Ophthalmology · Richmond, VANPI 1689964488

Payments from drug & device makers

$663in general payments, 2019–2025

Across 15 payments — averaging $44.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Tarsus Pharmaceuticals, Inc.$204
AbbVie$154
Amgen$134
Galderma Laboratories, L.p.$104
Revance Therapeutics, Inc.$48
Alcon$20

What the payments were for

Food & beverage$61493%
Education$497%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Tarsus Pharmaceuticals, Inc.	1	$204
AbbVie(2 entities)	6	$154
Amgen	3	$134
Galderma Laboratories, L.p.	2	$104
Revance Therapeutics, Inc.	2	$48
Alcon	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XDEMVY$204

How this compares

$663 in reported general payments places this provider in the 40th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia →

Medicare billing

Part B allowed, 2024

$305,887

Medicare patients

596

Services billed

3,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ErythromycinErythromycin Base	346	$3,002
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	94	$849
ValacyclovirValacyclovir Hcl	40	$487
Doxycycline Hyclate	27	$204
Methylprednisolone	29	$143
Ciprofloxacin Hcl	11	$112
Cephalexin	27	$74

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Richmond

Ali TabassianRichmond$2.1M
Ethnie JonesRichmond$2M
John O KeefeRichmond$44K
Byron LaddRichmond$32K
Thomas JenkinsRichmond$26K
Ryan DeasyRichmond$19K
Jessica RandolphRichmond$18K
David JacobsRichmond$16K
Nikisha RichardsRichmond$16K
Kenneth PriceRichmond$14K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →